Will potential study participants choose a vaccine trial over getting access to PrEP?
The US Preventive Services Task Force released its final ruling in *JAMA*.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
Results of CDC-Funded Local Projects for MSM and Transgender People Unveiled at Prevention Conference
Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.
This study identified some information about transgender women's sexual networks in Los Angeles. But activists worry about privacy and the potential that the surveillance method will be used in HIV criminalization cases.
HIV Prevalence Among Transgender Women Lower Than Previously Estimated, but Rates May Not Be Going Down, New CDC Study Finds
New data from CDC show that rates of HIV infection among transgender women in the U.S. are lower than previous estimates, but still, nearly 45% of black transgender women are living with HIV.
The findings mark a crucial point in the history of PrEP delivery among trans women, as they offer clarity for health care providers, PrEP outreach campaigns, and trans women using estradiol as feminizing hormone therapy.
Many trans women living with HIV may contract the virus because they or their sexual partners are intravenous drug users (IDU), finds a new study.